Pro-Dex (PDEX) Set to Release Quarterly Earnings on Thursday

Pro-Dex (NASDAQ:PDEX) is expected to release its Q1 2027 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $0.67 per share and revenue of $20.40 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2027 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 3:00 PM ET.

Pro-Dex (NASDAQ:PDEX) last posted its quarterly earnings data on Thursday, September 3rd. The medical instruments supplier reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.20. The business had revenue of $20.41 million during the quarter, compared to the consensus estimate of $19.20 million. Pro-Dex had a return on equity of 25.13% and a net margin of 17.62%. On average, analysts expect Pro-Dex to post $3.09 EPS for the current fiscal year and $3.36 EPS for the next fiscal year.

Pro-Dex Stock Down 2.5%

NASDAQ:PDEX opened at $60.66 on Tuesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.10 and a quick ratio of 2.45. The firm’s 50-day moving average price is $65.34 and its 200-day moving average price is $55.98. The company has a market capitalization of $195.93 million, a PE ratio of 18.57 and a beta of 0.04. Pro-Dex has a 1-year low of $28.40 and a 1-year high of $77.00.

Analysts Set New Price Targets

Several equities research analysts recently commented on PDEX shares. Ascendiant Capital Markets boosted their price objective on shares of Pro-Dex from $70.00 to $74.00 and gave the stock a “buy” rating in a research note on Friday, September 11th. Zacks Research raised shares of Pro-Dex from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 15th. Finally, Weiss Ratings lowered shares of Pro-Dex from a “buy (b)” rating to a “hold (c+)” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Pro-Dex currently has an average rating of “Buy” and a consensus target price of $74.00.

Insider Activity

In other news, CEO Kirk Richard Lee Van, Jr. sold 19,235 shares of the stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $60.58, for a total transaction of $1,165,256.30. Following the sale, the chief executive officer owned 79,993 shares in the company, valued at $4,845,975.94. This represents a 19.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Alisha Charlton sold 2,300 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $61.30, for a total transaction of $140,990.00. Following the sale, the chief financial officer directly owned 21,870 shares of the company’s stock, valued at $1,340,631. This trade represents a 9.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 22,300 shares of company stock valued at $1,351,657 over the last ninety days. Corporate insiders own 48.00% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc (NASDAQ:PDEX) designs, develops and manufactures powered surgical instruments and related products for the medical device industry. The company primarily serves original equipment manufacturers that incorporate Pro-Dex instruments into surgical systems sold under their own brands.

Its products include battery-powered and pneumatic handpieces, rotary instruments, micro-drills, saws, controllers and other specialized equipment used in orthopedic, dental, ophthalmic and other surgical applications.